Payment overview · 2025
General Payments
$181.00
10 reported records · 7 companies
Healthcare provider profile · identity verified
Douglas A. Layton, DO
Allopathic & Osteopathic Physicians|Family Medicine · POLK CITY, IA · NPI 1831159193
Verified facts
What the public records show
CMS Open Payments records show Douglas A. Layton, DO received $181.00 in general payments during 2025 across 10 reported records.
Lilly USA, LLC accounted for 40.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Nurtec Odt.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $72.49 | 40.0% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $25.94 | 14.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.44 | 10.2% | 1 | 2025 |
| Ascensia Diabetes Care Us Inc. | Unresolved — no canonical attribution shown | $18.23 | 10.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.15 | 10.0% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $14.03 | 7.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.72 | 7.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $181.00 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $39.42 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $33.07 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $33.07 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $25.94 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $18.15 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $14.03 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.72 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $13.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 93 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
61 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
65 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
93 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
95 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 370 | 100 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 259 | 80 |
| Levothyroxine Sodium | Levothyroxine Sodium | 248 | 56 |
| Lisinopril | Lisinopril | 235 | 65 |
| Metformin Hcl Er | Metformin Hcl | 155 | 48 |
| Omeprazole | Omeprazole | 153 | 37 |
| Losartan Potassium | Losartan Potassium | 152 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 151 | 45 |
| Amlodipine Besylate | Amlodipine Besylate | 140 | 40 |
| Gabapentin | Gabapentin | 132 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 128 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 124 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 99 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 97 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 96 | 28 |
| Ozempic | Semaglutide | 95 | 24 |
| Prednisone | Prednisone | 95 | 71 |
| Mounjaro | Tirzepatide | 93 | 13 |
| Levetiracetam | Levetiracetam | 86 | 13 |
| Baclofen | Baclofen | 81 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 81 | 21 |
| Famotidine | Famotidine | 73 | 21 |
| Warfarin Sodium | Warfarin Sodium | 70 | suppressed |
| Cefdinir | Cefdinir | 69 | 58 |
| Escitalopram Oxalate | Escitalopram Oxalate | 69 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 67 | 28 |
| Trazodone Hcl | Trazodone Hcl | 66 | 22 |
| Jardiance | Empagliflozin | 65 | 20 |
| Furosemide | Furosemide | 63 | 15 |
| Meloxicam | Meloxicam | 63 | 21 |
| Farxiga | Dapagliflozin Propanediol | 61 | 17 |
| Simvastatin | Simvastatin | 61 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 60 | 15 |
| Potassium Chloride | Potassium Chloride | 55 | 12 |
| Eliquis | Apixaban | 54 | suppressed |
| Allopurinol | Allopurinol | 51 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 50 | 15 |
| Finasteride | Finasteride | 50 | 16 |
| Metformin Hcl | Metformin Hcl | 48 | 14 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 44 | 11 |
| Benazepril Hcl | Benazepril Hcl | 42 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 40 | 11 |
| Ezetimibe | Ezetimibe | 39 | 11 |
| Bupropion Xl | Bupropion Hcl | 38 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 38 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 37 | 31 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 37 | 25 |
| Ipratropium Bromide | Ipratropium Bromide | 36 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | 11 |
| Mirtazapine | Mirtazapine | 36 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 35 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 34 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 33 | suppressed |
| Cephalexin | Cephalexin | 31 | 20 |
| Diazepam | Diazepam | 31 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | suppressed |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 30 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 29 | suppressed |
| Levofloxacin | Levofloxacin | 28 | 26 |
| Amoxicillin | Amoxicillin | 27 | 14 |
| Carvedilol | Carvedilol | 27 | suppressed |
| Rybelsus | Semaglutide | 27 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 26 | suppressed |
| Irbesartan | Irbesartan | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 25 | suppressed |
| Ketoconazole | Ketoconazole | 24 | 14 |
| Spironolactone | Spironolactone | 24 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 23 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 20 | suppressed |
| Lactulose | Lactulose | 20 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 19 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 18 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Budesonide | Budesonide | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 13 |
| Amantadine | Amantadine Hcl | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 16 | suppressed |
| Clarithromycin | Clarithromycin | 15 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 15 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 15 | suppressed |
| Acetylcysteine | Acetylcysteine | 14 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 11 | suppressed |
| Movantik | Naloxegol Oxalate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $181.00 · 10 records | Lilly USA, LLC | KISUNLA, MOUNJARO, NURTEC ODT, REXULTI, TZIELD, Wegovy, ZAVZPRET, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error